Clinical trials: Mesenchymal Stem Cells
Autism, Autism Spectrum Disorder
hCT-MSC in Children With Autism Spectrum Disorder
The purpose of this Phase II study is to determine the efficacy of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) for improving social communication abilities in children with autism spectrum disorder…
- Trial name
- IMPACT (NCT04089579)
- Testing
- Cord Tissue Mesenchymal Stromal Cells
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Joanne Kurtzberg, MD
COVID-19
A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19.
- Trial name
- NCT04348435
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Hope Biosciences Research Foundation
Cleft Lip and Palate
Use of Mesenchymal Stem Cells for Alveolar Bone Tissue Engineering for Cleft Lip and Palate Patients
The aim of this study is to perform the bone tissue engineering to reconstruct the alveolar bone defect in cleft lip and palate patients using mesenchymal stem cells from deciduous dental pulp associated with a collagen and…
- Trial name
- NCT01932164
- Testing
- maxillary alveolar graft by tissue engineering, Bone tissue engineering using mesenchymal stem cells
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- Hospital Sirio-Libanes
Cerebral Palsy
A Study of UCB and MSCs in Children With CP: ACCeNT-CP
The main purpose of this study is to estimate change in motor function 12 months after treatment with a single dose of allogeneic umbilical cord blood (AlloCB) or repeated doses of umbilical cord tissue-derived mesenchymal…
- Trial name
- ACCeNT-CP (NCT03473301)
- Testing
- Infusion of allogeneic umbilical cord blood, Infusion of MSCs
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Joanne Kurtzberg, MD
COVID-19
A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19
Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19.
- Trial name
- NCT04349631
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Hope Biosciences Research Foundation
Epidermolysis Bullosa
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
This is an open-label, single institution, phase II study in patients with epidermolysis bullosa (EB). The underlying hypothesis is that the infusion of bone marrow or umbilical cord blood from a healthy unaffected donor will…
- Trial name
- NCT01033552
- Testing
- Cyclophosphamide, Fludarabine, Anti-thymocyte globulin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
COVID-19
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for patients suspected to have COVID-19.
- Trial name
- NCT04362189
- Testing
- HB-adMSC
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hope Biosciences Research Foundation
Epidermolysis Bullosa
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
This is a single-institution, phase II study to determine the event-free survival at 1 year post allogeneic transplant and serial mesenchymal stem cell (MSC) infusions from a related donor (HLA identical, mismatched or…
- Trial name
- NCT02582775
- Testing
- Thymoglobulin, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bronchopulmonary Dysplasia
A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD
A multicenter, placebo-controlled, randomized, dose escalation, safety, and tolerability study of UNEX-42 in infants born at <27 weeks of gestational age (GA) at high risk for bronchopulmonary dysplasia (BPD).
- Trial name
- NCT03857841
- Testing
- UNEX-42, Phosphate-buffered saline
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- United Therapeutics
Graft-Versus-Host Disease
Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids
Background: Sometimes after stem cells are transplanted, donor cells attack the recipient s cells and cause tissue damage. This is called acute graft-versus-host-disease (GVHD).
- Trial name
- NCT02379442
- Testing
- MSC
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Periapical Periodontitis
Encapsulated Mesenchymal Stem Cells for Dental Pulp Regeneration.
To compare the dental survival in a period of one year of mature permanent teeth with apical lesion following the administration of encapsulated Mesenchymal Stem Cells under a regenerative endodontic procedure and a conventional…
- Trial name
- RanoKure (NCT03102879)
- Testing
- Regenerative Endodontic Procedure, Conventional Root Canal Treatment
- Where
- Chile
- Volunteers
- 36 people
- Sponsor
- Universidad de los Andes, Chile